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Abstract
This paper studies the influence of apoptosis in the dynamics of the HIV infection. A
new modeling of the healthy CD4+ T-cells activation-induced apoptosis is used. The
parameters of this model are identified by using clinical data generated by monitoring
patients starting Highly Active Anti-Retroviral Therapy (HAART). The sampling
of blood tests is performed to satisfy the constraints of dynamical system parameter
identification. The apoptosis parameter, which is inferred from clinical data, is then
shown to play a key role in the early diagnosis of immunological failure.
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1 Introduction
Infection with HIV typically causes a progressive decay in the functionality
and the number of CD4+ T-lymphocytes that may ultimately lead to the
lethal Acquired Immune Deficiency Syndrome (AIDS). Since the first iden-
tification of the disease in 1981, intensive studies have been carried out to
understand the fundamental HIV infection mechanisms. Several mechanisms
have been involved in the loss of CD4+ T-cells and this topic is one of the
most controversial issues in recent AIDS research.
T-cell loss appears to be due to direct destruction by the virus (direct virus-
induced cytolisis) or to defective T-cell generation. In 1991, apoptosis, also
called programmed cell death, has been suggested as another mechanism re-
sponsible for T-cell depletion during the progression of the HIV infection and
an extensive body of recent literature is supporting this hypothesis
(Pantaleo, G. et al. (1995), Herbein, G. et al. (1998), Marie-Lise Gougeon et al.
(1999), Ahr, B. et al. (2004), Badley, A.D. (2005), Yun Yue, F. et al. (2005),
Stan, G.B. et al. (2008)). In HIV-infected patients, both infected and un-
infected cells undergo exaggerated apoptosis but, remarkably, the vast ma-
jority of the cells that undergo apoptosis are uninfected (Vassena, L. et al.
(2007)). Furthermore, the level of apoptosis in HIV infected patients is cor-
related to the levels of circulating CD4+ T-cells and the stage of the disease
(Vassena, L. et al. (2007)), which reinforces the idea that apoptosis plays a
major role in the death of the lymphocytes.
Mathematical analysis of the HIV/AIDS infection has been actively studied
since the middle of the 90’s (Perelson, A.S. et al. (1997), Perelson, A.S. et al.
(1999)). Nowadays, more specific topics related to the HIV dynamics are being
studied, and amongst them, treatment scheduling, resistance emergence and
HAART therapy drugs effect. Some particular therapy regimes and/or struc-
tured treatment interruptions schemes have been proposed to enhance the
immune response and eventually lead to the long-term immunological control
of HIV (Wodarz, D. and Nowak, M. (1999), Zurakowski, R. and Teel, R.A.
(2006), Chang, H. and Astolfi, A. (2007)). Recently, the correlation existing
between treatment interruptions and emergence of resistant viral strains has
also been analyzed (Zurakowski, R. and Wodarz, D. (2007), Smith, R.J. (2006)).
Concerning the sensitivity of the HIV response to treatment and drug ef-
fects, the interested reader is referred to (Smith, R. and Wahl, M. (2004))
and (Khalili, S. and Armaou, A. (2008)).
The mathematical models which are mainly used consist of a set of non-
linear Ordinary Differential Equations (ODEs) which aim at modeling the
long-term interaction between the immune system and the virus. These mod-
els take into consideration several biological phenomena that influence the
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infection process, but, to the best of our knowledge, only Stan, G.B. et al.
(2008) proposed a model incorporating the activation-induced apoptosis phe-
nomena. In Stan, G.B. et al. (2008), a modification of the model presented
in Adams, B.M et al. (2004) is presented and its goal is to propose a simple
yet realistic HIV-immune system dynamical interaction model which incorpo-
rates the observed activation-induced apoptosis phenomenon and permits the
mathematical analysis of its effect on the simulated HIV infection.
Among a general population of HIV infected patients starting a new ther-
apy, some individuals will eventually undergo a so-called immunological fail-
ure. The main contribution of this paper is to predict such failures based on
the identification of an apoptosis parameter. Immunological failure is clin-
ically declared when the amount of CD4 T-cells remains under the level
of 200/mm3 during 6 months of efficient treatment (Delfraissy, JF. (2005);
U.S. Dept. Health and Human Services (2006); Ouattara, D. (2005)). A treat-
ment is defined as efficient if it yields a decrease of the viral load below the
detectability threshold of 50 copies/ml and keeps the viral load below this
limit afterwards. A central paradox for HIV patients who are in immuno-
logical failure is that their viral load seems too low to be able to deplete
the CD4+ population by direct killing alone. In this respect, previous stud-
ies (Ouattara, D. (2005), Ouattara, D. (2007), Ouattara, D. et al. (2008))
relate immunological failure to a malfunctioning thymus which is unable to
produce a sufficient amount of healthy CD4+ T-cells. Herein, a different point
of view is argued and it is shown that estimation of the value of a specific
apoptosis parameter in the transient stage of the infection also allows to di-
agnose immunological failure. This approach is supported by results derived
from real clinical data provided by the CHU de Nantes (Nantes University
Hospital) in France.
The outline of this paper is as follows. In Section 2.1 some elementary modeling
of the HIV/AIDS dynamics in the form of a 3-Dimensional (3D) continuous-
time model is reviewed. In Section 2.2, this 3D model is modified in order
to take into account the activation-induced apoptosis phenomenon which di-
rectly affects the population of uninfected CD4+ T-cells. Section 2.3 presents
a 4-Dimensional continuous-time model which takes into account not only the
apoptosis phenomenon, but also the dynamics of cytotoxic T-lymphocytes cells
(CTL). In Section 3 the identifiability of the new models is proved and the
identification method used for the parameter estimation is described. Work-
ing assumptions and the clinical trial design are summarized in Section 4.
The main results of this study which concern the relation existing between
activation-induced apoptosis and immunological failure are presented in Sec-
tion 5. Finally, Section 6 offers some concluding remarks as well as some open
questions.
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2 Mathematical modeling of apoptosis
To describe the HIV infection dynamics, several authors attempted to de-
sign various mathematical models which are mostly either deterministic (e.g.
Perelson, A.S. et al. (1997), Perelson, A.S. et al. (1999), Adams, B.M et al.
(2004)) or stochastic (?, Khalili, S. and Armaou, A. (2008)). An extensive
overview of the different types of models that have been proposed for treat-
ing AIDS affected patients using anti-retroviral drug therapies is provided in
(Tan, W.Y and Wu, H. (2005)). In particular, recent models tend to have a
growing number of variables representing several cell populations involved in
the infection process. For example, in (Khalili, S. and Armaou, A. (2008)),
the proposed model has 11 differential equations and more than 10 param-
eters while the basic model described in (Perelson, A.S. et al. (1999)), and
(Nowak, M.A (2002)) has only 3 differential equations and 6 parameters.
Complex models may be helpful to incorporate some of the phenomena and
fine details known about the HIV infection. However, the complexity of such
models easily becomes a drawback when considering their rigorous mathemat-
ical analysis or if these are to be used for control purposes. Due to the large
number of parameters involved and the lack of clinical data, it is often required
to simplify models and to restrict their analysis to essential phenomena only.
This is the approach chosen in this paper.
2.1 A Basic 3D model of the HIV infection dynamics
In this section, a review of the basic 3-Dimensional (3D) continuous-time
model of the HIV infection dynamics as described by Perelson, A.S. et al.
(1999) and Nowak, M.A (2002) is presented. This model, given hereafter, in-





T˙ = s− δT − βTV,
T˙ ∗ = βTV − µT ∗,
V˙ = kT ∗ − cV.
(1)
In this model, the state variable T (in CD4/mm3) represents the amount of
uninfected CD4+ T-cells, T ∗ (in CD4/mm3) represents the amount of infected
CD4+ T-cells and V (in RNA copies/ml) represents the amount of free virions.
Free virus particles infect uninfected T-cells at a rate proportional to both T
and V (βTV ). They are removed from the system at the rate cV . In model (1),
it is assumed that healthy CD4+ T-cells are produced at a constant rate s (this
production typically occurs in the thymus). The terms δT and µT ∗ represent
the death rates of uninfected and infected cells, respectively. The terms 1/δ,
1/µ, and 1/c are the life-times of the uninfected CD4+ T-cells, infected CD4+
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T-cells and virions, respectively.
2.2 A 3D apoptosis modeling
Apoptosis, also called programmed cell death, is an important biological pro-
cess that eliminates selected cells for the benefit of the whole organism. The
"decision" for apoptosis can come from the cell itself, or be induced from
its surrounding environment. In the special case of lymphocytes, apoptosis
plays an important role in optimizing the immune system by compensating
lymphocytes proliferation through the elimination of cells that have become
ill or ineffective. When apoptosis is not influenced by the presence of other
cells, its effect can be included in the death rate of each cell (represented
by the term −δT ). However, this is not the case for environment depen-
dent apoptosis. As reported in Pantaleo, G. et al. (1995) and Badley, A.D.
(2005), lymph nodes of HIV-infected individuals contain a high percentage
(with respect to uninfected individuals) of uninfected cells which are in an
apoptotic state − that is which are ready to enter an apoptopic process.
These cells are prematurely marked for apoptosis due to the presence of
several chemical messengers, such as the glycoprotein gp120 (soluble or ex-
pressed on the surface of infected cells and virions), proteins (Tat, Nef, Vpr),
and also the membrane-bound TNF-alpha on the surface of macrophages (see
Herbein, G. et al. (1998), Marie-Lise Gougeon et al. (1999), Zauli, G. et al.
(1999) and Stewart, S.A et al. (2000), Wang, J.et al. (2001), Ahr, B. et al.
(2004) for more details). For the sake of obtaining a model which is able to
qualitatively capture the activation-induced apoptosis phenomenon without
becoming too complex for its analysis, it is assumed that all the potential
apoptosis-inducing factors are directly correlated with the concentration of
HIV-infected CD4+ T-cells. To incorporate this environment-dependent apop-
tosis into the model given in (1), the healthy T-cells dynamics are modified
as follows:
T˙ = s− δT − βTV − δAT
where δA denotes the death rate of uninfected CD4+ T-cells related to activation-
induced apoptosis. δA depends on the amount of chemical messengers released
by the infected CD4+ T-cells and thus depends on T ∗:
T˙ = s− δT − βTV − δA(T ∗)T.
Assuming that the concentration of the chemical messengers inducing apop-
tosis is proportional to T ∗, and more specifically that δA(T
∗) = AT ∗, gives:
T˙ = s− δT − βTV − AT ∗T.
where A is a non negative parameter that represents the "apoptosis rate" (also
called apoptosis parameter) of uninfected CD4+ T-cells when in presence of in-
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fected CD4+ T-cells. This modeling is directly derived from (Stan, G.B. et al.
(2008)) to which the interested reader is referred for details and in-depth math-




T˙ = s− δT − βTV−ATT ∗,
T˙ ∗ = βTV − µT ∗,
V˙ = kT ∗ − cV.
(2)
Equilibrium points of the 3DA model:
By setting T˙ = T˙ ∗ = V˙ = 0 and solving the corresponding set of equations, it
can be shown that there are only 2 equilibrium points for model (2).
(1) HIV free equilibrium:
T (eq1) = s/δ, T ∗(eq1) = 0, V (eq1) = 0.
(2) HIV pathological equilibrium:
T (eq2) = µc
βk
, T ∗(eq2) = sβk−δµc
µ(βk+Ac)
, V (eq2) = k(sβk−δµc)
µc(βk+Ac)
.
Note that an efficient treatment typically leads to undetectable viral loads,
which, in the case of this simplified model, can be approximated by a situation
where the drug therapy drives the patient to the HIV free equilibrium. It will
be shown in Sections 3 and 5 that the proposed model (2) is identifiable and
thus can be used to identify the apoptosis parameter A in the transient stage
of the therapy response.
For completeness, an elementary dynamics for the cytotoxic T-lymphocytes
(CTL) has been added to the HIV infection dynamics considered in (2). This
is done in the following Section 2.3. The identifiability of models (2) and (3)
is discussed in Section 3. Results are displayed in Section 5.
2.3 A 4D apoptosis modeling
In this section, a 4-Dimensional HIV model which takes into account the
apoptosis phenomenon and the dynamics of the HIV specific CTL cells is
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T˙ = s− δT − βTV−ATT ∗,
T˙ ∗ = βTV − µT ∗ − qT ∗Tctl,
T˙ctl = λ+ aTT
∗Tctl − αTctl,
V˙ = kT ∗ − cV.
(3)
In this model, CTL cells are produced by the thymus at a constant rate λ.
CTL cells are activated when put in contact with infected CD4+ T-cells.
Furthermore, establishment of the CTL response typically depends on the
concentration of CD4+ T-cells (Wodarz, D. and Nowak, M. (1999)). Conse-
quently, one can consider that CTL cells proliferate at a rate aTT ∗Tctl pro-
portional to T , T ∗ and Tctl. The term αTctl represents the death rate of the
CTL cells. CTL cells eliminate infected CD4+ T-cells at a rate qT ∗Tctl. This
form of the CTL dynamics has been introduced in (Ouattara, D. (2006)) to
which the reader is referred for additional information. Note that the pro-
grammed cell death of CTL cells is still a controversial issue and may be a
consequence of immune stimulation with no direct link to HIV pathogenesis
( Estaquier, J. et al. (1994)). Therefore, apoptosis of CTL cells is not explic-
itly included in model (3).
Equilibrium points of the 4DA model
Solving the system of equilibrium equations of model (3), it can be shown that
it has 3 equilibrium points which are given hereafter.
(1) HIV free equilibrium:
T (eq1) = s/δ, T ∗(eq1) = 0, T
(eq1)
ctl = λ/α, V
(eq1) = 0
(2) HIV pathological equilibrium:
T (eq2) = Z1, T




ctl = −µc−βkZ1qc , V









∆ = (−acβks+ αβkAc+ αβ2k2 − ac2µδ)2
−4acβkδ(−λqcβk − λqc2A+ ac2µs− αµc2A− αµcβk)
(3) The third solution of the system of equilibrium equations corresponds to
negative state variables for the average parameters values at steady state.
Thus, this equilibrium point has no physical interest.
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3 Identifiability and identification method
3.1 Identifiability of model (2) and model (3)
Since available measurements typically contain the total (uninfected and in-
fected) CD4+ T-cells concentration and the concentration of free virions, the
output measurements for model (2) are y1 = T + T
∗ and y2 = V . According
to the identifiability theory presented in Xia, X. and Moog,C.H. (2003), it is
shown that the proposed 3D model (2) is algebraically identifiable from the
considered output measurements (y1 and y2).
Let θ1 = s, θ2 = δ, θ3 = β, θ4 = A, θ5 = µ, θ6 = k, θ7 = c. The parameters θi
are identifiable from the measured outputs since
rank(Γ) = rank
∂(y˙1, · · · , y(4)1 , y¨2, · · · , y
(4)
2 )
∂(θ1, · · · , θ7)
= 7. (4)
Straightforward but tedious computations show that the rank condition (4) is
satisfied for model (2). In particular, ten measurements at least (5 for y1 and
5 for y2, i.e 5 blood samples) are required to obtain a first estimate of the
7 parameters of model (2). Considering output measurements y1 = T + T
∗,
y2 = V and y3 = Tctl, similar computations show that the 4DA model is also
algebraically identifiable. However, 15 measurements at least (5 for y1, 5 for y2
and 5 for y3, i.e 5 blood samples) are required to compute the 11 parameters
of model (3).
3.2 The estimation procedure: a Monte-Carlo approach
The estimation method used in this paper is based on the Monte-Carlo ap-
proach introduced in Ouattara, D. (2005). This method is heuristic and relies
on the non-linear simplex optimization method which is an extension of the
simplex optimization approach proposed in Filter, R.A. and Xia, X. (2003). It
addresses the problem of high variance of the simplex optimization algorithm
with respect to the data set and the initial conditions. This is achieved by
drawing a large number of random realizations of initial conditions and taking
as estimated values for the parameters the median value of the results obtained
for each random initial condition. Its main advantage is that the obtained re-
sults are stable and robust with respect to the algorithm initialization values. If
the considered model is identifiable, the algorithm returns the parameters esti-
mates and the IQR (interquartile range) of the distribution of each estimated
parameter. The IQR is defined as the distance between the 75th percentile and
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the 25th percentile of the distribution. It measures the dispersion of the results
around the real optimum and gives an important information about the confi-
dence on the results. The robustness of this Monte-Carlo method with respect
to noisy data was presented in (Ouattara, D. (2006)), (Ouattara, D. (2007))
and (Ouattara, D. et al. (2008)). The estimation algorithm is implemented in
a software available at IRCCyN Web software (2007) that allows parameter
identification for HIV ODE infection models of individual patients. Estimation
results presented in Section 5 were generated with this software. Figure 1 is a
typical example of how a specific output of the simulated model fits the exper-
imental data. It shows the simulated time evolution of the viral load compared
to experimental data for patient 03. In the forthcoming sections, parameter























Fig. 1. Simulated viral load compared to clinical data for patient 3 (model 3DA)
estimation is done using the algorithm described above. The reader is referred
to (Ouattara, D. (2005)), (Ouattara, D. (2006)), (Ouattara, D. (2007)) and
(Ouattara, D. et al. (2008)) for more details about this algorithm.
4 Working context
4.1 Assumptions
Parameters in the mathematical models of the HIV/AIDS infection are related
to the immunological or virological status of the patient. For instance, s is the
natural production of CD4 T-cells by the thymus. So, a low value for s is
representative of a badly damaged immune system. On another hand, a large
value for A indicates an important activation-induced apoptosis phenomenon.
By estimating the parameters of these models from clinical observations, a
numerical quantification of the importance of these biological phenomena be-
comes possible.
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In particular, the aim of this work is to show that immunological failure
can be predicted by modeling and analyzing the activation-induced apop-
tosis phenomenon during the transient stage of the dynamics. Until now,
immunological failure was alternatively related to a low value of the param-
eter s (Ouattara, D. (2005)), which typically means that the depletion of
CD4+ T-cells is essentially due to a low production level of healthy CD4+ T-
cells by the thymus. Recent literature suggests that the eradication of CD4+
T-cells is mostly due to a strong activation-induced apoptosis phenomenon
(Pantaleo, G. et al. (1995), Herbein, G. et al. (1998), Marie-Lise Gougeon et al.
(1999), Badley, A.D. (2005), Yun Yue, F. et al. (2005), Stan, G.B. et al. (2008)).
In this analysis, it is considered that each of the life-time parameters appearing
in (2), i.e. δ, µ, and c, has a fixed, common value for all patients. Indeed, it
was shown in (Moog, C.H. et al. (2007)) that the life-time parameters do not
vary significantly from one patient to another. Furthermore, a fixed common
level of CD4+ T-cells production s is assumed, which amounts to assume that
all patient have a healthy thymus. Finally, note that the parameters β and k
do not a priori reflect any intrinsic success or failure property of the immune
system (they characterize the virulence of the infection and potentially include
the treatment effects). Therefore, only the value of A computed from the
transient response determines the immune system status. Detailed hypotheses
and results are presented in Section 5.
4.2 The EDV05 clinical trial design
The EDV05 trial was initiated at the CHU of Nantes in February 2005, and 6
patients were included in the first part of this trial. In 2007, 6 other patients
were enrolled. These patients did respect a set of enrollment criteria and a
specific sampling policy was applied. These are described below.
4.2.1 Enrollment criteria of patients
The main conditions for each patient (Female or Male) to be included in the
trial were as follows:
• aged over 18 years,
• having been infected by the HIV-1 or HIV-2 type virus,
• not showing any resistance to the administrated treatment,
• no co-infection with HBV (Hepatitis B virus) or HCV (Hepatitis C virus)
during the 6 months preceding their inclusion into the trial,
• starting an anti-Retroviral treatment at the beginning of the trial.
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All the patients start a treatment (not necessarily the same) at the beginning
of the trial (Day d0). Day d0 is not the same for all the patients. The third
condition enables avoiding any viral resistance which is not taken into account
in the presented model. In fact, most of the patients enrolled in this trial,
especially the first six, are naive of any treatment at d0. The fourth condition
was introduced to avoid dealing with HIV patients whose clinical state is
influenced by other infections. Note that 25% (5%) of HIV patients, in France,
are co-infected by HCV (HBV) (see Delfraissy, JF. (2005)). Table 1 gathers
data about the 12 patients enrolled in the trial.
Patient ID Day d0 Year of birth (age at d0)
01 14 March 2005 1956 (49 years)
02 14 March 2005 1967 (38 years)
03 22 March 2005 1962 (43 years)
04 22 March 2005 1964 (41 years)
05 04 April 2005 1967 (38 years)
06 02 May 2005 1970 (35 years)
07 12 February 2007 1963 (44 years)
08 02 April 2007 1971 (36 years)
09 14 May 2007 1976 (31 years)
10 04 June 2007 1968 (39 years)
11 31 December 2007 1948 (59 years)
12 31 December 2007 1958 (49 years)
Table 1
The 12 patients enrolled in the EDV05 trial. Day d0 is the first day of the trial for
the patient (the day of enrollment). The average age at d0 is 41.8 years.
4.2.2 The data sampling scheduling
The measured data are the viral load, the total CD4 T-cells count and the
total CTL T-cells count. Eleven blood samples were taken during 3 months
according to the planning described in Figure 2. The day di is equal to the
day d0 + i. After the initiation of the treatment, at day d0, the viral load
drops exponentially with an average time response of 7 days. One explanation
for this lies in the fact that the patients do not present any drug resistance.
The viral load stabilizes below the detectability level of 50 copies/ml after
3 weeks. As can be observed in Figure 1, the dynamics of the infection is
strongly affected by the treatment at the beginning of the trial. Thus, blood
samples are taken frequently in the first days of the trial, i.e. in the tran-
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Data Day of measurement
P01 P02 P03 P04 P05 P06 P07 P08 P09 P10 P11 P12
1 d0 d0 d0 d0 d0 d0 d0 d0 d0 d0 d0 d0
2 d1 d1 d1 d1 d1 d1 d4 d4 d4 d4 d4 d4
3 d2 d2 d2 d2 d2 d2 d7 d8 d7 d7 d7 d7
4 d4 d4 d7 d7 d4 d4 d9 d9 d9 d8 d9
5 d11 d11 d13 d13 d11 d11 d11 d11 d11 d11 d11 d11
6 d21 d18 d21 d20 d18 d21 d14 d14 d15 d14 d14 d14
7 d28 d32 d30 d27 d32 d31 d17 d17 d17 d18 d18 d17
8 d45 d49 d45 d48 d44 d44 d29 d30 d29 d32 d31 d29
9 d60 d60 d62 d62 d64 d59 d49 d47 d45 d46 d45 d43
10 d74 d74 d76 d79 d74 d74 d57 d60 d59 d60 d60 d57
11 d91 d92 d91 d90 d91 d92 d92 d91 d94 d91 d88 d85
Fig. 2. Planning of data measurements during the clinical trial. d0 is the first day
of the trial for the patient. di is equal to the day d0 + i.
sient response of the infection dynamics, when measurements contain more
information about the dynamics which is not the case when the system sta-
bilizes. More precisely, to collect relevant information about the dynamics, 6
or 7 blood samples are taken during the first 20 days. This enables a first
estimation of all the parameters of the 3DA model given in (2). From day
30 to day 90, only 4 or 5 other samples are taken with a sampling rate of
about 15 days. Since the measured viral load values depend on the laboratory
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protocol used to quantify the RNA copies (Prud’homme, I.T. et al. (1998);
Fiches Techniques de la Firme Roche (2003); Berger, A. et al. (2005); Galli R. et al.
(2005); Israel Ballard, K. et al. (2005)), it was decided for each patient to per-
form all the measurements of the viral load at the same time with the same
protocol. Thus, the 11 blood samples of each patient have been kept frozen (at
−80◦C) until the end of the trial. The measurements were done at the same
time using the Roche Taqman 48TM test, with a detectability threshold of 50
copies/ml.
5 Results
In this section identification of the parameters of model (2) is performed, and,
in particular, the identification of parameter A. Recall that life-time parame-
ters are set to inter-patient constant values: δ = 0.01 day−1, µ = 0.05 day−1, c =
0.3 day−1. To our best knowledge on parameter uncertainties of the HIV/AIDS
infection (Wei, L. et al. (1995), Ho, D.D et al. (1995), Table 2.1 of Perelson, A.S. et al.
(1999), Ouattara, D. (2005)), parameter c ranges in the interval [0.1 ; 0.65]
with a mean value close to 0.3 day−1. From the EDV05 results (when not fix-
ing any parameter), c ranges approximately in the interval [0.1 ; 0.3] with a
median 1 at 0.28 day−1. The results of the identification of µ and δ in previ-
ous studies were obtained based on the same Monte-Carlo approach described
above. They suggest that µ has a median close to 0.05 day−1 and δ has a me-
dian close to 0.01 day−1. Also, parameter s is fixed at 6CD4mm−3 day−1. This
reduces to the assumption that the thymus of all patients is healthy. Parame-
ters β and k determine the virulence of the infection and include treatment’s
effect; thus, they don’t reflect any property of the immune system. So, the
only varying parameter which reflects the immune system’s status is A.
In particular, identification was performed using only the first six blood sam-
ples for each patient. Indeed, the goal is to be able to diagnose immunological
failure as soon as possible after starting a new therapy. The inclusion of the
transient response samples is essential for an accurate identification of the pa-
rameters whereas the last blood samples typically do not contain significant
additional dynamical information. However, the identification from the whole
set of blood samples available has also been performed and the corresponding
results are in accordance with those obtained using the first six blood samples
only.
Results are listed in Table 2 which shows that patients 03, 07 and 11 have
the highest values of parameter A. Furthermore, the interquartile range for
1 The "median" is used instead of the "mean" since it is a more robust statistical
criterion than mean with respect to noise in the data.
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parameter A (IQR(A)) for these patients is almost isolated from the IQR(A)
of other patients.
In fact, the immunological failure of patient 03 was clinically confirmed after 3
months of monitoring. From a clinical point of view, the first six data points for
patient 07 suggest that he was also going through immunological failure, but
starting d30 he entered a non-observance phase. Furthermore, no monitoring
of this patient was possible after the end of the trial. Thus, the decision about
the status of patient 07 remains controversial. On another hand, patient 11
was 59 years old at the trial time and is the oldest among the 10 patients which
have been included. In this special case, a high value of the apoptosis parame-
ter rather indicates poor dynamics of the immune system which is standard at
the age of 60. No immunological failure was observed for the 9 other patients.
Immunological failure is predicted after less than 3 weeks of monitoring as
displayed in Table 2. In this case, the effect of activation-induced apoptosis
is detrimental to the immune system since the high apoptosis rate results in
the auto-elimination of many healthy CD4+ T-cells. For the other patients,
A is too small to have a consequent effect on the immune system. Note that
the model has no inter-patient prediction ability since parameters identifica-
tion is derived for each patient alone and based on his own clinical data. The
conclusion of table 2 is that the identification of the apoptosis parameter in
model (2) gives a hint for the diagnosis of immunological failure. The pecu-
liarities of each patient such as therapy adherence or age have nevertheless to
be considered afterwards to make the final clinical decision.
Results of the 4DA model
Even though similar results are obtained when using models (2) and (3), nu-
merical results of model (3) are not explicitly depicted in this paper. In fact,
the amount of specific-HIV CTL lymphocytes is not measurable in practice. In-
deed, the measured CTL count is the total amount of CTL cells in the plasma
which may not be fully due to the HIV infection as it typically includes the
CTL cells due to other infections also. In addition, for a fixed amount of data
points, identification of a higher order system with additional parameters is
typically less accurate than identification of the basic three dimensional model.
For the above reasons, identification of the model (3) is not fully tractable and
is not presented here.
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Pat. ID β k A IQR(A)
01 1.94E-07 0.04 5.26E-08 [2.55E − 09; 1.58E − 04]
02 3.27E-07 0.21 1.17E-07 [4.05E − 09; 7.36E − 05]
03 8.24E-07 0.41 1.25E-03 [2.80E − 04; 9.43E − 03]
04 7.10E-08 293.00 7.66E-08 [4.19E − 09; 2.77E − 05]
05 3.94E-07 0.004 6.24E-06 [3.44E − 09; 4.81E − 03]
06 1.21E-07 46.80 4.22E-07 [7.91E − 09; 5.14E − 04]
07 2.43E-06 0.008 6.51E-03 [4.41E − 03; 2.72E − 02]
08 8.15E-07 0.002 5.17E-08 [2.07E − 09; 7.13E − 04]
09 7.23E-07 0.003 1.01E-05 [5.52E − 09; 1.58E − 03]
10 6.16E-07 0.008 2.44E-06 [3.63E − 09; 1.61E − 03]
11 1.79E-07 0.012 9.26E-03 [8.42E − 03; 1.71E − 02]
12 2.56E-07 0.002 2.49E-06 [2.21E − 08; 1.04E − 03]
Table 2
Model 3DA parameters of the 12 patients of the EDV05 trial. Estimation done with
the first 6 blood samples with s = 6CD4mm−3d−1.
6 Conclusion
In this paper, the influence of activation-induced apoptosis on the HIV dynam-
ics was studied and it was shown that activation-induced apoptosis may char-
acterize immunological failure depending on its intensity. The two main con-
tributions are as follows. First, the activation-induced apoptosis phenomenon
was incorporated into the basic 3D model of the HIV infection (Section 2.2).
Second, it was shown that identification of the apoptosis parameter based on
ad hoc clinical data allows to predict the immunological failure of patients (Sec-
tion 5). These results could also help in designing new anti-HIV therapies based
on the regulation of activation-induced apoptosis factors in HIV infected pa-
tients. These therapies could include some interleukins such as IL-2, IL-7 and
IL-15 whose anti-apoptotic effect has been reported (Ahr, B. et al. (2004),
Vassena, L. et al. (2007)). The idea of studying the apoptosis phenomenon
was suggested by recent research papers relating the decline of CD4+ T-cells
to programmed cells death (Pantaleo, G. et al. (1995), Herbein, G. et al.
(1998), Marie-Lise Gougeon et al. (1999), Ahr, B. et al. (2004), Badley, A.D.
(2005), Yun Yue, F. et al. (2005), Stan, G.B. et al. (2008), Vassena, L. et al.
(2007)). After testing the identifiability of the newly apoptosis compliant
model and explaining the estimation procedure of the parameters, it was
shown that the so called apoptosis parameter identified from real clinical
data is a good alternative predictor of immunological failure. Previous stud-
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ies (Ouattara, D. (2005), Ouattara, D. (2007), Ouattara, D. et al. (2008))
relate the decline of the CD4+ T-cells to a low production rate of uninfected
cells due to a damaged thymus. Whether immunological failure is predomi-
nantly due to a badly damaged thymus or to an important activation-induced
apoptosis phenomenon remains an open question. Further research including
clinical data that evaluates the thymus status for HIV infected patients may
help in understanding the real reason behind the depletion of CD4+ T-cells.
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